ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

OMGA Omega Therapeutics Inc

1.85
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Omega Therapeutics Inc NASDAQ:OMGA NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.85 1.61 1.87 0 01:00:00

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

01/06/2023 12:00pm

GlobeNewswire Inc.


Omega Therapeutics (NASDAQ:OMGA)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more Omega Therapeutics Charts.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in two upcoming investor conferences.

Jefferies Healthcare Conference

Fireside ChatDate: Thursday, June 8, 2023Time: 8:30 a.m. ET

Goldman Sachs 44th Annual Global Healthcare ConferenceFireside ChatDate: Wednesday, June 14, 2023Time: 2:40 p.m. PT / 5:40 p.m. ET

Live webcasts of the fireside chats will be available on the Investors & Media section of the Company's website at www.omegatherapeutics.com. Archived replays will be available on the same website for approximately 90 days.

About Omega Therapeutics

Omega Therapeutics is a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines to treat or cure a broad range of diseases. By pre-transcriptionally modulating gene expression, Omega’s approach enables precision epigenomic control of nearly all human genes, including historically undruggable and difficult-to-treat targets, without altering native nucleic acid sequences. Founded in 2017 by Flagship Pioneering following breakthrough research by world-renowned experts in the field of epigenetics, Omega is led by a seasoned and accomplished leadership team with a track record of innovation and operational excellence. The Company is committed to revolutionizing genomic medicine and has a diverse pipeline of therapeutic candidates derived from its OMEGA platform spanning oncology, regenerative medicine, multigenic diseases including immunology, and select monogenic diseases.

For more information, visit omegatherapeutics.com, or follow us on Twitter and LinkedIn.

Contact:
Eva Stroynowski
617.949.4370
estroynowski@omegatx.com

1 Year Omega Therapeutics Chart

1 Year Omega Therapeutics Chart

1 Month Omega Therapeutics Chart

1 Month Omega Therapeutics Chart